Ultragenyx Pharmaceutical, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.
| Earnings Date | 11/4/2026 |
As of June 30, 2026, Ultragenyx Pharmaceutical, Inc. has 98.60M shares outstanding.
| Shares Outstanding | 98.60M |
As of June 30, 2026, Ultragenyx Pharmaceutical, Inc. maintains a current ratio of 1.73, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.73 |
| Quick Ratio | 1.40 |
| Interest Coverage | -6.46 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -45.60, reflecting losses generated across the asset base. The company generates approximately 464,416.99 in revenue per employee across its workforce of 1,351.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.30 indicates how many times Ultragenyx Pharmaceutical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -45.60 |
| Revenue Per Employee | 464,416.99 |
| Employee Count | 1,351.75 |
| Inventory Turnover | 2.30 |
Over the twelve months ended June 30, 2026, Ultragenyx Pharmaceutical, Inc. recorded 3.28M in income tax expense. The company reported a pretax loss of -509.62M and -512.90M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 3.28M |
Over the twelve months ended June 30, 2026, Ultragenyx Pharmaceutical, Inc. generated 627.78M in revenue and converted that into -512.90M in net income, yielding earnings per share of -5.10. EBITDA reached -433.42M, while operating income came in at -462.31M.
| Revenue | 627.78M |
| Gross Profit | 521.57M |
| Operating Income | -462.31M |
| Pretax Income | -509.62M |
| Net Income | -512.90M |
| EBITDA | -433.42M |
| EBIT | -462.31M |
| Earnings Per Share (EPS) | -5.10 |
These figures are as of June 30, 2026. Total book value stands at -254.71M, with working capital of 223.20M providing operational flexibility.
| Cash & Cash Equivalents | 255.59M |
| Net Debt | -109.41M |
| Equity (Book Value) | -254.71M |
| Book Value Per Share | -2.58 |
| Working Capital | 223.20M |
Ultragenyx Pharmaceutical, Inc. produced -424.52M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.88M in capital expenditures, free cash flow totaled -432.40M - equivalent to -4.30 per share.
| Operating Cash Flow | -424.52M |
| Capital Expenditures | -7.88M |
| Free Cash Flow | -432.40M |
| FCF Per Share | -4.30 |
Over the twelve months ended June 30, 2026, Ultragenyx Pharmaceutical, Inc. posted a gross margin of 83.08, reflecting its pricing power and cost economics. The operating margin of -73.64 and net profit margin of -81.70 provide insight into operational efficiency.
| Gross Margin | 83.08 |
| Operating Margin | -73.64 |
| Pretax Margin | -81.18 |
| Profit Margin | -81.70 |
| EBITDA Margin | -69.04 |